Pharmabiz
 

Carrington reports on advances development of GelSite injectable drug delivery technology

TexasFriday, August 22, 2003, 08:00 Hrs  [IST]

Carrington Laboratories Inc reports results obtained from an animal study of its GelSite technology demonstrating that the polymer undergoes resorption from the site of injection. In this study, the GelSite polymer was administered as a liquid that subsequently gels in the animal. The study, sponsored by DelSite Biotechnologies in collaboration with Southern Research Institute, demonstrated that the majority of the in situ gelled polymer was removed from the site in 5-8 weeks. In addition, the research team, using a GelSite formulation, successfully obtained data from an animal model, demonstrating up to a 7-day delivery of a bioactive protein of interest. "The results of these studies are encouraging," said Dr. Kenneth (Bill) Yates, president of DelSite. "These data are a key step as we continue to obtain information necessary to demonstrate the suitability of GelSite technology as an injectable delivery platform for proteins and peptides." Additional studies are planned to further evaluate the safety and functionality of the GelSite technology as an injectable controlled release delivery system.

 
[Close]